All In Biotech

Drug Trial Radar · NCT05229562

A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants

An Open-Label, Parallel-Group, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BIIB122 in Healthy Adult Japanese, Chinese, and Caucasian Participants

Last checked: Nov 19, 2026Latest source record: Apr 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

84

Actual

Start

Feb 17, 2022

Primary completion

Sep 7, 2022

Study completion Sep 7, 2022

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Feb 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study will be looking at an investigational drug, BIIB122, in healthy adult Japanese, Chinese, and Caucasian participants. The main goal of the study is to compare the drug level achieved in the body, between the different ethnic groups, after single and multiple doses of BIIB122. Researchers also want to see if single and multiple doses of BIIB122 are safe and if healthy participants can tolerate given doses of BIIB122.

Conditions

  • Healthy Volunteer

Interventions

  • BIIB122Drug

    Administered as specified in the treatment arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Plasma Concentration (Cmax) of BIIB122Time frame: Cohorts 1,2 and 3: At multiple time points post-dose on Days 1 to 4, and at Day 10; Cohort 4: At multiple time points post-dose on Day 1, Pre-dose on Days 2 to 9, Pre-dose and at multiple time points post-dose on Days 10 to 13, and at Day 20
  2. Time to Reach Maximum Observed Plasma Concentration (Tmax) of BIIB122Time frame: Cohorts 1,2 and 3: At multiple time points post-dose on Days 1 to 4, and at Day 10; Cohort 4: At multiple time points post-dose on Day 1, Pre-dose on Days 2 to 9, Pre-dose and at multiple time points post-dose on Days 10 to 13, and at Day 20
  3. Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24h) of BIIB122Time frame: Cohorts 1,2 and 3: At multiple time points post-dose on Days 1 to 4, and at Day 10; Cohort 4: At multiple time points post-dose on Day 1, Pre-dose on Days 2 to 9, Pre-dose and at multiple time points post-dose on Days 10 to 13, and at Day 20
  4. Cohorts 1,2 and 3: Area Under the Concentration-Time Curve From Time 0 to Time of the Last Measurable Concentration (AUClast) of BIIB122Time frame: Cohorts 1,2 and 3: At multiple time points post-dose on Days 1 to 4, and at Day 10
  5. Cohorts 1,2 and 3: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of BIIB122Time frame: Cohorts 1, 2 and 3: At multiple time points post-dose on Days 1 to 4, and at Day 10
  6. Cohort 4: Cmax of BIIB122 at Steady State (Cmax,ss)Time frame: Cohort 4: Pre-dose and at multiple time points post-dose on Days 10 to 13
  7. Cohort 4: Tmax of BIIB122 at Steady State (Tmax,ss)Time frame: Cohort 4: Pre-dose and at multiple time points post-dose on Days 10 to 13
  8. Cohort 4: AUC of BIIB122 Within a Dosing Interval at Steady State (AUCtau,ss)Time frame: Cohort 4: Pre-dose and at multiple time points post-dose on Days 10 to 13
  9. Cohort 4: Accumulation Ratio (AR) for AUC Within a Dosing Interval (AUCtau)Time frame: Cohort 4: Pre-dose and at multiple time points post-dose on Days 10 to 13
  10. Cohort 4: AR for CmaxTime frame: Cohort 4: Pre-dose and at multiple time points post-dose on Days 10 to 13

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Anaheim Clinical Trials, LLC

    Anaheim, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.